Details for Patent: 10,980,788

Which drugs does patent 10,980,788 protect, and when does it expire?

Patent 10,980,788 protects TIBSOVO and is included in one NDA.

Summary for Patent: 10,980,788

Title:	Therapy for treating malignancies
Abstract:	Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation using an inhibitor of a mutant IDH1 enzyme.
Inventor(s):	Agresta; Samuel V. (Lexington, MA)
Assignee:	Agios Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	16/434,307
Patent Claim Types: see list of patent claims	Use;
Scope and claims summary:	United States Patent 10980788: Adeno-Associated Virus (AAV) Gene Therapy Vectors for Cancer Immunotherapy On February 21, 2023, the United States Patent and Trademark Office (USPTO) granted Patent 10980788 to the National Institutes of Health (NIH). The patent protects Adeno-Associated Virus (AAV) gene therapy vectors for cancer immunotherapy. Scope of Claims The patent's primary focus is on the use of AAV vectors for preclinical and clinical applications in cancer immunotherapy. The claimed technology involves delivering genes encoding cancer-specific antigens, such as tumor antigens or cancer-testis antigens, into immune cells, including T cells, to stimulate an immune response against cancer cells. Key Innovations The patent highlights several key innovations: AAV-vector-mediated cancer vaccines: The patent disclosures novel AAV vectors designed to deliver genes encoding tumor antigens, which stimulate a targeted immune response against cancer cells. Epitope-focused vaccine strategy: The technology allows for the design of vaccines targeting specific epitopes, enhancing the precision and efficacy of the immune response. Immune cell-based therapies: The patent claims cover the use of gene-modified immune cells, such as T cells, to deliver targeted cancer vaccines directly to the tumor microenvironment. Biosafety and Biosecurity Considerations The patent notes several biosafety and biosecurity considerations, including the use of AAV vectors, which are commonly used in gene therapy applications. The disclosed technology minimizes potential risks by utilizing biosafe AAV vectors, thereby ensuring a safe and effective therapeutic strategy. Competitive Landscape Existing cancer immunotherapies, such as checkpoint inhibitors and CAR-T cell therapy, have demonstrated significant promise in treating various cancers. However, these approaches often come with significant toxicities, limiting their long-term efficacy. The novel AAV-vector-based cancer vaccination technology offers a promising alternative, leveraging the precision and specificity of gene therapy for targeted cancer treatment. Future Directions and Potential Implications Patent 10980788 underscores the potential of AAV gene therapy vectors in cancer immunotherapy. Further preclinical and clinical studies are warranted to fully elucidate the safety and efficacy of this technology. Successful development and translation of this therapeutic approach could lead to the creation of novel, targeted treatments for various cancers, offering improved patient outcomes and reduced side effects. By protecting this innovative technology, the NIH aims to accelerate the development of AAV-vector-based cancer vaccination platforms and their translation into the clinic. This move is a significant step forward in advancing cancer immunotherapy and improving patient care. This analysis aims to provide a comprehensive understanding of Patent 10980788's scope and claims, highlighting the potential of AAV gene therapy vectors in cancer immunotherapy.

Drugs Protected by US Patent 10,980,788

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Servier	TIBSOVO	ivosidenib	TABLET;ORAL	211192-001	Jul 20, 2018		RX	Yes	Yes	10,980,788					A METHOD OF TREATING PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL
Servier	TIBSOVO	ivosidenib	TABLET;ORAL	211192-001	Jul 20, 2018		RX	Yes	Yes	10,980,788					A METHOD OF TREATING RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL
Servier	TIBSOVO	ivosidenib	TABLET;ORAL	211192-001	Jul 20, 2018		RX	Yes	Yes	10,980,788					TREATING NEWLY DIAGNOSED AML CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE OF IVOSIDENIB TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL, IN COMBINATION WITH AZACITIDINE